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Corrections
Re: J Child Adolesc Psychopharm 23:208–213, 2013
Hans-Christoph Steinhausen and Dorte Helenius, ‘‘The Association Between Medication
for Attention-Deficit/Hyperactivity Disorder and Cancer,’’ J Child Adolesc Psychopharm 23:208–213, 2013.
The authors have submitted the following correction
to their article:
In our recent publication, we analyzed the risk of having adiagnosis of cancer in attention-deficit/hyperactivity disorder
(ADHD) patients receiving various medications or no medication.
Unfortunately, our previous risk analysis (Table 3 in the article)
was incorrect and did not use the data from the prescription reg-
ister in the most suitable way. The prescription database was
initiated on January 1, 1995. However, in our previous analyses
patients became at risk at birth and switched medical status
whenever they received medication after January 1, 1995. This
means that a number of cases with an unknown cancer status
before January 1, 1995 may have been included in the no medi-
cation subgroup during their whole observation period. Further-
more, we assumed that individuals were without medication until
January 1, 1995.
In the revised analysis we have used additional data from the
Danish National Patient Registry on the occurrence of cancer in the
period 1977–1993. When reanalyzing the data by Cox regression
we followed the individuals from January 1, 1995 or date of birth if
born later than this date and included treatment as a time-varying
covariate. This follow-up ended December 31, 2009. Therefore, all
cases having a diagnosis of cancer or dying before January 1, 1995
were not included in the survival analysis. Furthermore, the model
was stratified on year of birth (divided into before, in, or after 1994)
and sex because otherwise the proportional hazard assumption was
not fulfilled.
A total of N = 60 cases were diagnosed with cancer after January
1, 1995. The revised risk model revealed the following findings.
Receiving methylphenidate (MPH) was associated with 89% de-
crease in the risk of cancer compared to the nomedication subgroup
(HR: 0.11, 95% CI: 0.01–0.82) and mixed medication (MX) (in-
cluding MPH as the largest component) was associated with 83%
decrease in the risk of cancer compared to the no medication sub-
group (HR: 0.17, 95% CI: 0.06–0.50). Finally, receiving antide-
pressants (AD) was associated with an almost threefold increased
risk of cancer in comparison to the no medication subgroup (HR:
2.70, 95% CI: 1.04–7.01). Although receiving antipsychotics (AP)
was associated with a twofold risk of cancer, this result was not
significant (HR: 1.99, 95% CI: 0.46–8.59). When excluding the
MX subgroup from the analyses leaving N = 54 cases occurring
from January 1, 1995 onwards, the protective MPH subgroup effect
remained significant (HR: 0.09, 95% CI: 0.01–0.64) whereas the
AD and AP subgroup effects were not significant anymore (AD:
HR: 1.88, 95% CI: 0.73–4.85; AP: HR: 1.52, 95% CI: 0.35–6.53).
The revised survival analysis based on the newly defined obser-
vation period is shown in Figure 1.
The comparability of the groups under treatment is fundamental
to the investigation of treatment effects. Confounding by indication
has been described as the most important limitation of observa-
tional studies. Among others, prognostic factors may influence
treatment decisions and bias the estimates of the treatment effects.
Controlling for known prognostic factors may reduce this bias but it
is always possible that an overlooked or unknown factor may have
exerted an effect. To avoid this bias, we calculated propensity
scores based on age at diagnosis of ADHD (divided into five groups
with equal frequencies), sex, year of birth (divided into five groups
with equal frequencies), and comorbid disorders in additional an-
alyses controlling for underlying systematic patterns. Comorbid
disorders diagnosed according to ICD-10 from 1994 onwards were
considered in major groups (main and secondary F-codes of the
ICD-10; the F9 main group did not include F90 since all patients
had this disorder) only prior to medication in the medicated groups
and over the total observation period until cancer or date of cen-
suring in the non-medicated subgroup. The results were in accor-
dance with the analyses reported above. However, the additional
variables in the propensity scores analysis may still have been too
limited to detect any underlying systematic similarities in the
treated groups.
In conclusion, both MPH and MX were protective of cancer
while AD was associated with an almost threefold risk of cancer
in comparison to the no medication subgroup. Excluding the MX
FIG. 1. Revised survival analysis findings (Kaplan–Meier curves)
for various drug subgroups. A color version of the figure is available
in the online correction at www.liebertpub.com/jcap.
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subgroup showed the same significant protective relation be-
tween MPH and cancer while the effects of AD and AP de-
creased and were not significant anymore. These findings imply
that MPH was not only no significant risk factor of cancer as
found in the previous analysis but rather a protective factor. The
protective effect of MX was most probably also driven by the
large MPH component in it. Furthermore, the impact of AD as a
risk factor was limited by the large confidence intervals in the
analysis including MX and by its lacking significance when
excluding MX.
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